CL2010001123A1 - Uso de piridin-3-ilmetil docosahexanoato para preparar un medicamento util para la prevencion y/o el tratamiento de enfermedades cardiovasculares (divisional solicitud 1848-07). - Google Patents

Uso de piridin-3-ilmetil docosahexanoato para preparar un medicamento util para la prevencion y/o el tratamiento de enfermedades cardiovasculares (divisional solicitud 1848-07).

Info

Publication number
CL2010001123A1
CL2010001123A1 CL2010001123A CL2010001123A CL2010001123A1 CL 2010001123 A1 CL2010001123 A1 CL 2010001123A1 CL 2010001123 A CL2010001123 A CL 2010001123A CL 2010001123 A CL2010001123 A CL 2010001123A CL 2010001123 A1 CL2010001123 A1 CL 2010001123A1
Authority
CL
Chile
Prior art keywords
docosahexanoate
ylmethyl
pyridin
treatment
cardiovascular diseases
Prior art date
Application number
CL2010001123A
Other languages
English (en)
Inventor
Jean Gardette
Frederique Bruen
Andre Delhon
Jean Francois Potoiseau
Severac Etienne Marty
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686083&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010001123(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of CL2010001123A1 publication Critical patent/CL2010001123A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/02—Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Uso del compuesto piridin-3-ilmetil docosahexanoato para el tratamiento de enfermedades cardiovasculares, arritmia, taquicardia, fibrilación, entre otras. (divisional solicitud 1848-2007).
CL2010001123A 2006-06-23 2010-10-13 Uso de piridin-3-ilmetil docosahexanoato para preparar un medicamento util para la prevencion y/o el tratamiento de enfermedades cardiovasculares (divisional solicitud 1848-07). CL2010001123A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0605649A FR2902659A1 (fr) 2006-06-23 2006-06-23 Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires

Publications (1)

Publication Number Publication Date
CL2010001123A1 true CL2010001123A1 (es) 2011-03-25

Family

ID=37686083

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001123A CL2010001123A1 (es) 2006-06-23 2010-10-13 Uso de piridin-3-ilmetil docosahexanoato para preparar un medicamento util para la prevencion y/o el tratamiento de enfermedades cardiovasculares (divisional solicitud 1848-07).

Country Status (38)

Country Link
US (2) US8034377B2 (es)
EP (1) EP2034999B9 (es)
JP (1) JP5053372B2 (es)
KR (1) KR101380128B1 (es)
CN (1) CN101472590A (es)
AR (1) AR061622A1 (es)
AT (1) ATE489091T1 (es)
AU (1) AU2007262958B2 (es)
BR (1) BRPI0713725A2 (es)
CA (1) CA2655570C (es)
CL (1) CL2010001123A1 (es)
CO (1) CO6150156A2 (es)
CR (1) CR10507A (es)
DE (1) DE602007010776D1 (es)
DK (1) DK2034999T3 (es)
EC (1) ECSP099039A (es)
ES (1) ES2355611T3 (es)
FR (1) FR2902659A1 (es)
GE (1) GEP20125464B (es)
HN (1) HN2008001771A (es)
HR (1) HRP20110086T1 (es)
IL (1) IL195562A (es)
MA (1) MA30584B1 (es)
MX (1) MX2009000103A (es)
MY (1) MY145985A (es)
NO (1) NO20090334L (es)
NZ (1) NZ573454A (es)
PL (1) PL2034999T3 (es)
PT (1) PT2034999E (es)
RS (1) RS51629B (es)
RU (1) RU2451672C2 (es)
SA (1) SA07280345B1 (es)
SI (1) SI2034999T1 (es)
TN (1) TNSN08527A1 (es)
TW (1) TWI389888B (es)
UA (1) UA96156C2 (es)
WO (1) WO2007147899A2 (es)
ZA (1) ZA200900334B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334536B1 (es) * 2008-04-11 2011-01-24 Universidad Complutense De Madrid Procedimiento para la obtencion selectiva de 12-hidroxi-9-cis-octadecenoato de (1,4:3,6-dianhidro-d-glucitol) utilizando lipasas inmovilizadas como catalizador.
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
CN102946904A (zh) * 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
FR2963790B1 (fr) 2010-08-11 2012-09-28 Pf Medicament Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
EP3443985B1 (en) 2010-08-23 2020-12-16 XBiotech, Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN102757444B (zh) * 2011-04-29 2016-02-10 南京信诺泰医药有限公司 具有一氧化氮供体性质的苯并呋喃类化合物
FR2998479B1 (fr) * 2012-11-27 2017-04-28 Pf Medicament Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
WO2016024283A1 (en) * 2014-08-12 2016-02-18 Praj Industries Limited Process for the preparation of triglycerides of epa and dha
US10441087B2 (en) 2015-02-24 2019-10-15 Sleep Number Corporation Mattress with adjustable firmness
WO2018150265A1 (en) 2017-02-16 2018-08-23 Xbiotech, Inc. Treatment of hidradenitis suppurativa
AU2018220635A1 (en) * 2017-02-20 2019-08-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hydrogen sulfide and/or nitrite in the treatment and prevention of Atrial Fibrillation
CN110950881A (zh) * 2018-09-27 2020-04-03 中国科学院上海药物研究所 一类三环类似物、其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133049C (es) 1966-02-24
JPS5967263A (ja) 1982-10-07 1984-04-16 Terumo Corp ペンタエン高級脂肪酸ピリジルアルコ−ルエステルおよびその製法
JPS5967264A (ja) 1982-10-08 1984-04-16 Terumo Corp 血小板凝集抑制剤
WO1984001899A1 (en) * 1982-11-16 1984-05-24 Georges Motschan New utilization of a unique vitamin or a combination of various vitamins
JPS6034947A (ja) * 1983-08-05 1985-02-22 Terumo Corp ドコサヘキサエン酸誘導体およびそれを用いた血小板凝集阻止剤
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
US6015821A (en) 1995-05-01 2000-01-18 Horrobin; David Frederick Nicotinic acid esters and pharmaceutical compositions containing them
IL118092A0 (en) 1995-05-03 1996-09-12 Smithkline Beecham Plc Antibacterial compounds their preparation and pharmaceutical compositions containing them
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
ATE305810T1 (de) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
US8729124B2 (en) * 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
WO2004091603A1 (fr) * 2003-04-07 2004-10-28 Clinigenetics Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
EP1466597A1 (en) * 2003-04-07 2004-10-13 Clinigenetics Use of dha esters to control or prevent cardiovascular diseases
KR20060004939A (ko) 2003-04-17 2006-01-16 베링거 인겔하임 인터내셔날 게엠베하 임산부를 위한 종합 비타민 및 미네랄 보충제

Also Published As

Publication number Publication date
CO6150156A2 (es) 2010-04-20
WO2007147899A3 (en) 2008-03-13
KR20090024794A (ko) 2009-03-09
MY145985A (en) 2012-05-31
RU2451672C2 (ru) 2012-05-27
RS51629B (en) 2011-08-31
AU2007262958B2 (en) 2011-10-27
FR2902659A1 (fr) 2007-12-28
AU2007262958A1 (en) 2007-12-27
TWI389888B (zh) 2013-03-21
RU2008152248A (ru) 2010-07-27
PT2034999E (pt) 2011-01-19
ECSP099039A (es) 2009-02-27
WO2007147899A2 (en) 2007-12-27
TW200811108A (en) 2008-03-01
EP2034999B1 (en) 2010-11-24
JP2009544576A (ja) 2009-12-17
MX2009000103A (es) 2009-01-23
SI2034999T1 (sl) 2011-02-28
AR061622A1 (es) 2008-09-10
CN101472590A (zh) 2009-07-01
WO2007147899B1 (en) 2008-05-02
NO20090334L (no) 2009-03-04
IL195562A (en) 2012-06-28
KR101380128B1 (ko) 2014-04-11
ATE489091T1 (de) 2010-12-15
TNSN08527A1 (en) 2010-04-14
SA07280345B1 (ar) 2011-01-15
IL195562A0 (en) 2009-09-01
GEP20125464B (en) 2012-04-10
ZA200900334B (en) 2009-12-30
DK2034999T3 (da) 2011-01-24
EP2034999B9 (en) 2011-03-09
PL2034999T3 (pl) 2011-05-31
ES2355611T3 (es) 2011-03-29
HRP20110086T1 (hr) 2011-03-31
BRPI0713725A2 (pt) 2012-10-30
US8227479B2 (en) 2012-07-24
MA30584B1 (fr) 2009-07-01
UA96156C2 (ru) 2011-10-10
NZ573454A (en) 2010-10-29
JP5053372B2 (ja) 2012-10-17
US20090312354A1 (en) 2009-12-17
US20110237613A1 (en) 2011-09-29
CR10507A (es) 2009-02-05
DE602007010776D1 (de) 2011-01-05
US8034377B2 (en) 2011-10-11
HN2008001771A (es) 2011-01-24
EP2034999A2 (en) 2009-03-18
CA2655570A1 (en) 2007-12-27
CA2655570C (en) 2015-09-08

Similar Documents

Publication Publication Date Title
CL2010001123A1 (es) Uso de piridin-3-ilmetil docosahexanoato para preparar un medicamento util para la prevencion y/o el tratamiento de enfermedades cardiovasculares (divisional solicitud 1848-07).
CL2013003598A1 (es) Compuestos derivados de benzooxazepinona, moduladores de canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades seleccionadas de arritmias, insuficiencia cardiaca, angina, infarto al miocardio, diabetes, entre otras
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
ECSP077299A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
GT200600028A (es) Compuestos y composiciones como inhibidores de proteina kinasa
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
CL2008001994A1 (es) Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CL2012003226A1 (es) Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
ES2526606T3 (es) Composición farmacéutica sólida que comprende amlodipina y losartán
CL2008001157A1 (es) Compuestos derivados de quinolina-carboxamida, antagonistas de p2y12; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; composicion de una combinacion de dichos compuestos; y uso del compuesto en el tratamiento de trastornos cardiovasculares, tromboembolismo, infarto agudo al miocardio.
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
CU20070203A7 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
MY147247A (en) Organic compounds and their uses
CL2008002411A1 (es) Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras.
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CL2011000341A1 (es) Compuestos derivados de pirrolidinona sustituida, moduladores de la actividad de ar para la inhibicion de ntd; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de cancer, acne, hirsutismo, entre otras.